Jasper Therapeutics, Inc. — Director's Dealing 2023

Feb 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jasper Therapeutics, Inc. (JSPR)
CIK: 0001788028
Period of Report: 2023-02-02

Reporting Person: MARTELL RON (Director, President, CEO & Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-02	Stock Option (right to buy)	$1.78	A	1093831	Acquired	2033-02-02	Voting Common Stock (1093831)	Direct

Footnotes

F1: 1/4th of the shares subject to the option shall vest on February 2, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.